ZURICH, Switzerland, March 14 /PRNewswire/ -- The Scientific Steering
Committee of the European Commission today recommended the novel
Prionics(R)-Check LIA BSE-Test for the EU Surveillance Program. "With our new
BSE test, we are comprehensively equipped to meet future market needs today,"
says Dr. Bruno Oesch, CEO and Head of Research & Development at Prionics. The
Prionics(R)-Check LIA is the first rapid BSE test that is easy to use both
manually and when integrated into a fully automated system. The LIA was
designed to complement the most successful BSE test worldwide, the
Prionics(R)-Check WESTERN, which has established itself among BSE experts as
the reference for BSE rapid tests, due to its unmatched precision and
reliability. "The two tests form an ideal and 100 per cent reliable
complementary testing system able to meet the most diverse needs of our
customers," explains Prionics' Marketing Director, Karl Kalf.
The Prionics(R)-Check LIA was evaluated by the European Commission in a
field study carried out by BSE experts at two different national BSE reference
centers and four routine diagnostic laboratories. The large-scale study was
the first of its kind. It focused not only on the technical specifications of
the novel BSE test but also on its precision in field use, particularly under
adverse conditions. The Prionics(R)-Check LIA not only fulfilled all
requirements it also demonstrated 100 per cent sensitivity, underlining its
suitability for reliable detection of BSE animals. The test also exhibited
100 per cent specificity, which means that it would not incorrectly identify
samples from healthy animals as BSE positive. "The results of the EU study
prove that the test is unbeatable in sensitivity and specificity," says Kalf.
"Absolute reliability and high precision under field conditions represent the
ambitious and demanding criteria which must be met by any new test developed
by Prionics. Each individual result is important in consumer protection,
especially as substances derived from one single cow can reach between 200,000
and 400,000 (1) consumers."
Prionics AG is the world leader in the early diagnosis of prion diseases
such as Bovine Spongiform Encephalopathy ("Mad Cow disease") and scrapie. The
company shot to fame in 2000 when its BSE tests uncovered the devastating fact
that cattle across Europe had contracted Mad Cow disease. Prionics' research
and development efforts are focused on neurological and prion diseases. The
Prionics research team works closely with a network of prion and neurological
experts around the world, and the company is now considered an international
center of excellence in the diagnosis of prion diseases. Prionics AG is a ISO
9001 certified company and currently employs 80 people.
1. Opinion of the Scientific Steering Committee on the Human Exposure
Risk (HER) via food with respect to BSE -- Adopted on 10 December
SOURCE Prionics AG